Kluwer Academic Publishers eBooks · 2006 · 12 citations · 56 references
MedicineEndocrinologyPharmacologyDrug DesignDrug DiscoverySignal TransductionAllosteric Drug DesignEndocrine PharmacologyGlucagon-like Peptide-1 Receptor AgonistsLigand BindingReceptor PharmacologyOctreotide TherapySomatostatin PharmacologySomatostatin Signaling
Somatostatin was discovered in the laboratories of Professor R. Guillemin at the Salk Institute in La Jolla, California (Brazeau et al., 1973; Guillemin, 1992), and was first described as hypothalamic growth hormone (GH)-release inhibiting factor. Within a few years, more and more information accumulated about its ubiquitous distribution in different regions of the body, including the pancreas and gastrointestinal tract, and on its more general inhibitory functions on hormones such as insulin, glucagon, gastrin, and other gastrointestinal hormones, as well as on enzymes such as those from the exocrine pancreas. These characteristics suggested that somatostatin had enormous therapeutic potential, and early clinical investigations substantiated hopes for applications in the treatment of hypersecretory states
56
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Paul Brazeau, Wylie Vale, Roger Burgus et al. · Science · 1973 · 3.5K citations
SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
W. Bauer, U. Briner, W. Doepfner et al. · Life Sciences · 1982 · 1.3K citations
Yuichiro Yamada, Steven R. Post, K Wang et al. · Proceedings of the National Academy of Sciences · 1992 · 765 citations · Full text
LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN
E. P. Krenning, Wout A. P. Breeman, P.P.M. Kooij et al. · The Lancet · 1989 · 622 citations
Medicine, Endocrinology, Oncology +10